ACUTE REJECTION BY BELATACEPT DOSING FREQUENCY: RESULTS FROM A PHASE II STUDY OF KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Vincenti, F. [1 ]
Blancho, G. [2 ]
Durrbach, A. [3 ]
Grannas, G. [4 ]
Grinyo, J. [5 ]
Meier-Kriesche, U. [6 ]
Polinsky, M. [6 ]
Zhao, H. [6 ]
Larsen, C. [7 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hosp Nantes, Nantes, France
[3] Univ Hop Bicetre, Le Kremlin Bicetre, France
[4] Hannover Med Sch, Hannover, Germany
[5] Univ Hosp Bellvitge, Barcelona, Spain
[6] Bristol Myers Squibb, Lawrenceville, NJ USA
[7] Emory Univ, Atlanta, GA 30322 USA
来源：
TRANSPLANT INTERNATIONAL | 2016年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
V029
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Acute Rejection by Belatacept (Bela) Dosing Frequency: Results from a Phase II Study of Kidney Transplant Recipients.
    Vincenti, F.
    Blancho, G.
    Durrbach, A.
    Grannas, G.
    Griny, J.
    Meier-Kriesche, U.
    Polinsky, M.
    Zhao, H.
    Larsen, C.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 741 - 741
  • [2] Impact of the Microbiota on the Risk of Acute Cellular Rejection in Belatacept-Treated Kidney Transplant Recipients
    Herr, F.
    Bargiel, K.
    Taupin, J.
    Vernochet, A.
    Ciocan, D.
    Dekeyser, M.
    Durrbach, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S551 - S551
  • [3] SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES
    Grinyo, J.
    Charpentier, B.
    Medina Pestana, J.
    Vanrenterghem, Y.
    Vincenti, F.
    Shi, R.
    Agarwal, M.
    Thomas, D.
    Larsen, C.
    [J]. TRANSPLANT INTERNATIONAL, 2010, 23 : 59 - 60
  • [4] Safety Profile of Belatacept in Kidney Transplant Recipients from a Pooled Analysis of Phase II and Phase III Studies
    Grinyo, J.
    Charpentier, B.
    Pestana, J. Medina
    Vanrenterghem, Y.
    Vincenti, F.
    Shi, R.
    Agarwal, M.
    Thomas, D.
    Larsen, C. P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 83 - 83
  • [5] ACUTE REJECTION BY BELATACEPT 4-VS 8-WEEK DOSING: PHASE II STUDY 10-YEAR RESULTS
    Vicenti, F.
    Blancho, G.
    Durrbach, A.
    Grannas, G.
    Grinyo, J.
    Meier-Kriesche, U.
    Polinsky, M.
    Zhao, H.
    Larsen, C. P.
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 6 - 6
  • [6] Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection
    Cristea, O.
    Larsen, C.
    Badell, I.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 468 - 468
  • [7] Conversion to Belatacept in kidney Transplant Recipients with Chronic Antibody Mediated Rejection (CAMR)
    Moein, Mahmoudreza
    Gao, Shuqi
    Martin, Samuel
    Farkouh, Katie
    Li, Benson
    Ball, Angela
    Dvorai, Reut Hod
    Saidi, Reza
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (01) : S36 - S36
  • [8] Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients
    Del Bello, Arnaud
    Marion, Olivier
    Milongo, David
    Rostaing, Lionel
    Kamar, Nassim
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 215 - 227
  • [9] Acute Rejection in Older Kidney Transplant Recipients
    McAdams-DeMarco, M.
    James, N.
    Orandi, B.
    Walston, J.
    Segev, D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 497 - 498
  • [10] RENAL FUNCTION AT 2 YEARS IN KIDNEY TRANSPLANT RECIPIENTS SWITCHED FROM CYCLCOSPORINE OR TACROLIMUS TO BELATACEPT: RESULTS FROM THE LONG-TERM EXTENSION OF A PHASE II STUDY
    Grinyo, Josep
    Nainan, Georgy
    del Carmen Rial, Maria
    Steinberg, Steven
    Vincenti, Flavio
    Dong, Yuping
    Thomas, Dolca
    Kamar, Nassim
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 70 - 70
12345